Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form
Estudio de farmacovigilancia de una inmunoglobulina intravenosa regional (II): evaluación y comparación de una forma farmacológica mejorada
Read
4023
Timeswas read the article
789
Total PDF
3234
Total HTML
Article information
ISSN: 03010546Original language: English
DOI:10.1157/13095871
The statistics are updated each day
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 31 | 9 | 40 |
| 2025 11 | 120 | 58 | 178 |
| 2025 10 | 60 | 10 | 70 |
| 2025 9 | 40 | 13 | 53 |
| 2025 8 | 48 | 11 | 59 |
| 2025 7 | 43 | 7 | 50 |
| 2025 6 | 23 | 4 | 27 |
| 2025 5 | 28 | 10 | 38 |
| 2025 4 | 39 | 0 | 39 |
| 2025 3 | 33 | 9 | 42 |
| 2025 2 | 16 | 7 | 23 |
| 2025 1 | 23 | 11 | 34 |
| 2024 12 | 15 | 5 | 20 |
| 2024 11 | 18 | 8 | 26 |
| 2024 10 | 13 | 13 | 26 |
| 2024 9 | 12 | 11 | 23 |
| 2024 8 | 11 | 2 | 13 |
| 2024 7 | 14 | 3 | 17 |
| 2024 6 | 8 | 1 | 9 |
| 2024 5 | 11 | 2 | 13 |
| 2024 4 | 15 | 6 | 21 |
| 2024 3 | 19 | 4 | 23 |
| 2024 2 | 14 | 9 | 23 |
| 2024 1 | 25 | 6 | 31 |
| 2023 12 | 13 | 7 | 20 |
| 2023 11 | 9 | 3 | 12 |
| 2023 10 | 17 | 7 | 24 |
| 2023 9 | 15 | 1 | 16 |
| 2023 8 | 12 | 3 | 15 |
| 2023 7 | 12 | 3 | 15 |
| 2023 6 | 14 | 2 | 16 |
| 2023 5 | 23 | 3 | 26 |
| 2023 4 | 16 | 1 | 17 |
| 2023 3 | 5 | 1 | 6 |
| 2023 2 | 10 | 3 | 13 |
| 2023 1 | 7 | 5 | 12 |
| 2022 12 | 8 | 7 | 15 |
| 2022 11 | 17 | 6 | 23 |
| 2022 10 | 16 | 7 | 23 |
| 2022 9 | 9 | 5 | 14 |
| 2022 8 | 12 | 5 | 17 |
| 2022 7 | 16 | 6 | 22 |
| 2022 6 | 11 | 8 | 19 |
| 2022 5 | 12 | 8 | 20 |
| 2022 4 | 18 | 12 | 30 |
| 2022 3 | 14 | 12 | 26 |
| 2022 2 | 4 | 5 | 9 |
| 2022 1 | 14 | 6 | 20 |
| 2021 12 | 7 | 12 | 19 |
| 2021 11 | 8 | 5 | 13 |
| 2021 10 | 14 | 9 | 23 |
| 2021 9 | 10 | 14 | 24 |
| 2021 8 | 2 | 3 | 5 |
| 2021 7 | 11 | 9 | 20 |
| 2021 6 | 8 | 6 | 14 |
| 2021 5 | 14 | 12 | 26 |
| 2021 4 | 23 | 12 | 35 |
| 2021 3 | 8 | 11 | 19 |
| 2021 2 | 5 | 5 | 10 |
| 2021 1 | 7 | 4 | 11 |
| 2020 12 | 1 | 0 | 1 |
| 2018 2 | 1 | 0 | 1 |
| 2018 1 | 4 | 0 | 4 |
| 2017 12 | 2 | 0 | 2 |
| 2017 11 | 3 | 0 | 3 |
| 2017 10 | 7 | 0 | 7 |
| 2017 9 | 9 | 1 | 10 |
| 2017 8 | 5 | 1 | 6 |
| 2017 7 | 9 | 3 | 12 |
| 2017 6 | 17 | 2 | 19 |
| 2017 5 | 28 | 1 | 29 |
| 2017 4 | 20 | 15 | 35 |
| 2017 3 | 11 | 17 | 28 |
| 2017 2 | 8 | 2 | 10 |
| 2017 1 | 16 | 2 | 18 |
| 2016 12 | 29 | 4 | 33 |
| 2016 11 | 28 | 3 | 31 |
| 2016 10 | 41 | 1 | 42 |
| 2016 9 | 17 | 3 | 20 |
| 2016 8 | 20 | 2 | 22 |
| 2016 7 | 8 | 3 | 11 |
| 2016 6 | 26 | 1 | 27 |
| 2016 5 | 16 | 1 | 17 |
| 2016 4 | 24 | 6 | 30 |
| 2016 3 | 27 | 13 | 40 |
| 2016 2 | 20 | 17 | 37 |
| 2016 1 | 19 | 19 | 38 |
| 2015 12 | 20 | 14 | 34 |
| 2015 11 | 17 | 9 | 26 |
| 2015 10 | 26 | 11 | 37 |
| 2015 9 | 18 | 11 | 29 |
| 2015 8 | 14 | 2 | 16 |
| 2015 7 | 6 | 6 | 12 |
| 2015 6 | 9 | 1 | 10 |
| 2015 5 | 11 | 3 | 14 |
| 2015 4 | 20 | 16 | 36 |
| 2015 3 | 13 | 12 | 25 |
| 2015 2 | 20 | 12 | 32 |
| 2015 1 | 17 | 3 | 20 |
| 2014 12 | 22 | 8 | 30 |
| 2014 11 | 15 | 3 | 18 |
| 2014 10 | 15 | 5 | 20 |
| 2014 9 | 21 | 4 | 25 |
| 2014 8 | 20 | 1 | 21 |
| 2014 7 | 13 | 0 | 13 |
| 2014 6 | 20 | 0 | 20 |
| 2014 5 | 19 | 2 | 21 |
| 2014 4 | 9 | 2 | 11 |
| 2014 3 | 53 | 10 | 63 |
| 2014 2 | 31 | 11 | 42 |
| 2014 1 | 41 | 6 | 47 |
| 2013 12 | 41 | 3 | 44 |
| 2013 11 | 39 | 11 | 50 |
| 2013 10 | 32 | 8 | 40 |
| 2013 9 | 43 | 7 | 50 |
| 2013 8 | 49 | 9 | 58 |
| 2013 7 | 50 | 5 | 55 |
| 2013 6 | 23 | 5 | 28 |
| 2013 5 | 25 | 6 | 31 |
| 2013 4 | 22 | 8 | 30 |
| 2013 3 | 14 | 5 | 19 |
| 2013 2 | 9 | 4 | 13 |
| 2013 1 | 3 | 0 | 3 |
| 2012 12 | 1 | 0 | 1 |
| 2012 11 | 2 | 1 | 3 |
| 2012 10 | 0 | 1 | 1 |
| 2006 11 | 895 | 0 | 895 |
Show all
